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Background: Upon initial contact with a virus, host cells activate a series of cellular signaling cascades that facilitate
viral entry and viral propagation within the cell. Little is known about how the human astrovirus (HAstV) exploits
signaling cascades to establish an infection in host cells. Recent studies showed that activation of extracellular
signal-regulated kinase 1/2 (ERK1/2) is important for HAstV infection, though the involvement of other signaling
cascades remains unclear.
Methods: A panel of kinase blockers was used to search for cellular signaling pathways important for HAstV1
infection. To determine their impact on the infectious process, we examined viral gene expression, RNA replication,
and viral RNA and capsid protein release from host cells.
Results: Inhibitors of phosphoinositide 3-kinase (PI3K) activation interfered with the infection, independent of their
effect on ERK 1/2 activation. Activation of the PI3K signaling cascade occurred at an early phase of the infection,
judging from the timeframe of Akt phosphorylation. PI3K inhibition at early times, but not at later times, blocked
viral gene expression. However, inhibiting the downstream targets of PI3K activation, Akt and Rac1, did not block
infection. Inhibition of protein kinase A (PKA) activation was found to block a later phase of HAstV1 production.
Conclusions: Our results reveal a previously unknown, essential role of PI3K in the life cycle of HAstV1. PI3K
participates in the early stage of infection, possibly during the viral entry process. Our results also reveal the role of
PKA in viral production.
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The human astrovirus (HAstV), a member of the Astroviridae
family, is a small (28–30 nm) non-enveloped virus with a
6.8-kb, positive-sense RNA genome bound at the 5′ end
with the viral protein Vpg and polyadenylated at the 3′
end [1,2]. Human astroviruses cause gastroenteritis and
are a leading cause of viral diarrhea in young children.
HAstV type 1 (HAstV1) is the most prevalent of the eight
known HAstV serotypes in patients with gastroenteritis.
The viral genome of HAstV1 encodes two non-structural
proteins, nsp1a and nsp1ab, and a structural protein, the
viral capsid protein. The nsp1a protein is encoded by open* Correspondence: nakanish@ncgg.go.jp
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reproduction in any medium, provided the orreading frame (ORF) 1a, whereas the nsp1ab is produced
by a translational frameshifting mechanism that begins by
translating ORF1a, and then skips ORF1a’s stop codon by
shifting to the overlapping ORF1b [3,4]. The nsp1a and
nsp1ab polyproteins catalyze their own proteolytic process-
ing to produce functional viral proteins, including Vpg and
an RNA-dependent RNA polymerase [5]. These viral pro-
teins are believed to concertedly modulate cellular function
to facilitate viral propagation and directly participate in
viral RNA replication [2]. The viral capsid protein, encoded
by ORF2, is translated as an 87-kDa protein that under-
goes maturational processing by cellular enzymes and tryp-
sin to become the functional viral capsid [6,7]. The progeny
virions produced in the host cell can be released without
cell lysis, which appears to be linked to processing of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cellular apoptotic events [8-10].
Many viral infections are known to activate host cell
signaling pathways. The initial contact of viruses with a
host cell can trigger a series of signaling cascades that
facilitate viral entry and viral propagation within the cell
[11]. More specifically, this virus-induced signaling may
activate cellular mechanisms that viruses rely on for ini-
tiating infection, such as endocytosis, macrocytosis, and
phagocytosis as well as the mobilization of the actin
cytoskeleton [12].
One important cellular signaling pathway is the phospho-
inositide 3-kinase (PI3K)/Akt pathway, which regulates
diverse cellular activities, including cell growth, prolifer-
ation, survival, apoptosis, metabolism, migration, and
vesicular trafficking [13]. PI3K is activated when the
Src homology domain of its regulatory subunit, p85,
binds to auto-phosphorylated tyrosine kinase receptors,
non-receptor tyrosine kinases, or some viral proteins in
the cytoplasm [14]. The catalytic subunit of the acti-
vated PI3K, p110, then converts phosphatidylinositol
4,5-bisphosphate (PIP2) into the lipid messenger phos-
phatidylinositol (3,4,5)-trisphosphate (PIP3), which acti-
vates the downstream targets of PI3K. A primary target
is Akt, a serine/threonine protein kinase that modulates
diverse signaling pathways, such as cell survival, prolif-
eration, migration, differentiation, and apoptosis [15].
The binding of PIP3 allows Akt to form a complex with
PDK-1, which phosphorylates and activates Akt [15].
Another important target of PI3K is Rac1, a small G-
protein involved in cytoskeletal remodeling during lamelli-
podium formation, cell-to-cell contact, and cell migration
[16,17]. PIP3 activates Rac1 by mediating the activation
of Rac1-specific guanine exchange factors, such as T-
lymphoma invasion and metastasis actor 1 (Tiam1) or
Vav1 [16,17].
Another important group of cellular signaling path-
ways are those of the mitogen-activated protein kinases
(MAPKs), which include extracellular signal-regulated
kinases 1 and 2 (ERK1/2), p38, and c-Jun N-terminal ki-
nases (JNK). In the ERK1/2 pathway, signal is transduced
by activated receptor tyrosine kinases, the small G protein
Ras, Raf, and MAPK/ERK kinase1/2 (MEK1/2), which
then activate ERK1/2 through phosphorylation. Activated
ERK1/2 is known to regulate cell survival, proliferation,
and differentiation [18].
The intracellular signaling events that control HAstV1
infection are still not well understood. A study by Moser
and Schultz-Cherry [19] found that ERK1/2 are acti-
vated during the initial contact of HAstV with host cells
and are important for establishing HAstV infection. In
this study, we sought to identify additional signaling
pathways that play important roles in HAstV1 infection.
Our approach was to use a panel of kinase inhibitors totest whether the specific inhibition of individual signaling
pathways interferes with HAstV1 infection. We found that
inhibitors of PI3K activation blocked HAstV1 infection,
despite the fact that ERK activation was not inhibited.
This PI3K activation occurred at an early phase of the
infection, and apparently did not involve PI3K-mediated
phosphorylation of Akt. Thus, our results reveal a previ-
ously unknown role of PI3K in HAstV1 infection.
Results
Examining the effects of kinase inhibitors on viral capsid
protein expression
To search for the signaling pathways that are important
for HAstV1 infection, we examined various kinase blockers
inhibitors (Table 1) for their ability to block HAstV1 in-
fection of Caco-2 cells. Caco-2 cells were infected with
HAstV1 in the presence or absence of each kinase inhibi-
tor, and the presence of the inhibitor was maintained until
24 hours post-infection (hpi), when the cells were detected
for viral capsid protein by immunofluorescence. While
DMSO, the solvent for the inhibitors, did not interfere
with viral gene expression (Figure 1A, panels A and a),
4 μM staurosporine (Figure 1A, B and b), a general kin-
ase inhibitor, or 10 μM genistein (Figure 1A, C and c), a
general inhibitor for tyrosine kinases, blocked viral gene
expression. We noted that staurosporine treatment caused
modest cellular toxicity, evident by nuclear staining with
DAPI (Figure 1A, b) and by colorimetric assay for cell
viability (Figure 1C). However, the almost complete ab-
sence of cells positive for viral antigen suggests that the
drug was effective in blocking infection in the cells that
survived drug treatment. Consistent with the previously
reported requirement for ERK1/2 signaling in HAstV1
infection [19], U0126, a MEK1/2 inhibitor that blocks
ERK1/2 phosphorylation, also blocked viral gene expres-
sion (Figure 1A, D and d). Other members of the MAPK
family that we tested did not appear to be involved in
Figure 1 (See legend on next page.)
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Figure 1 Effects of kinase inhibitors on capsid protein expression following HAstV1 infection. (A) Caco-2 cells were infected with HAstV1
(MOI = 0.22) in the presence of solvent alone (DMSO, panels A and a), staurosporine (4 μM; B and b), genistein (10 μM; C and c), U0126 (20 μM;
D and d), SB 203580 (50 μM; E and e), or JNK inhibitor II (50 μM; F and f). The cells were fixed at 24 h post-infection (hpi), and then HAstV capsid
protein was detected by immunofluorescence. Each pair of panels shows, for the same field of cells, the staining patterns for the viral capsid
protein (anti-HAstV, A through F) and for cellular DNA (DAPI, a through f). (B) Caco-2 cells were infected with HAstV1 in the presence of various
kinase inhibitors, LY294002 (50 μM; panels A and a), wortmannin (1 μM; B and b), Triciribine, (10 μM; C and c), MK-2206 (10 μM; D and d),
NSC23766 (50 μM; E and e), Y27632 (50 μM; F and f), and H89 (10 μM; G and g). Each pair of panels shows, for the same field of cells, the
staining patterns for the viral capsid protein (A through G) and for cellular DNA (a through g). (C) Viability of Caco-2 cells infected with HAstV1 in
the presence of designated drugs was examined by colorimetric assay using WST-1 reagent (Takara). The absorbance of the cell culture medium
was measured at 450 nm versus a 650-nm reference. The vertical axis indicates arbitrary unit divided by the mean value of a solvent-only (DMSO)
control sample. The mean value obtained using three of each sample is presented as bar graph, with the standard deviation indicated as error
bar. Statistical significance, compared with the solvent control (DMSO) is indicated (*P < 0.05; **P < 0.01).
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203580, which blocks p38 activation (Figure 1A, E and e),
nor 50 μM JNK inhibitor II, which selectively inhibits JNK
(Figure 1A, F and f), had a significant effect on viral capsid
gene expression.
We were also able to confirm that ERK1/2 activation
occurs at an early stage of HAstV1 infection. The phos-
phorylation level of various kinases was examined at dif-
ferent times post-infection by Western blotting for both
phosphorylated and phosphorylation-independent epitopes
of each kinase (Figure 2A). The signal intensity of each
band relative to that of each mock-infected sample at
0.25 hpi is presented in Figure 2C. Compared with that
of the mock-infected sample, the phosphorylation levels
of ERK1/2 were noticeably elevated at the early time
points (0.25 hpi and 0.5 hpi) (Figure 2A, “pERK” and
Figure 2C, “ERK”). Similarly, the p38 phosphorylation
level appeared to be elevated at 0.25 hpi (Figure 2A,
“pp38” and Figure 2C, “p38”). A marginal increase in the
phosphorylation level of JNK was observed in the infected
cells throughout the time points examined (Figure 2A,
“pJNK” and Figure 2C, “JNK”). However, only the phos-
phorylation of ERK1/2, and not that of p38 and JNK, was
necessary for infection, judged from the results of the
capsid protein expression assay performed with inhibi-
tors specific to these kinases (Figure 1A). We noted that
the level of phosphorylated ERK1/2 increased at 8 hpi
(Figure 2A, right “pERK”), an observation not reported
earlier [19]. This is unlikely to be related to any infec-
tion event because phosphorylated ERK1/2 was similarly
elevated at this time point in the mock-infected sample
(left “pERK” panel).
Our search for additional HAstV1 infection-related
signaling pathways uncovered evidence for the import-
ance of PI3K activation. The PI3K inhibitor LY294002
(Figure 1B, panels A and a) effectively blocked post-
infection viral capsid expression, whereas the other PI3K
inhibitor, wortmannin (Figure 1B, panels B and b), was
slightly less effective, evidenced by the unusual punctatesignal of capsid protein. A possible explanation is that
although more potent than LY294002 in inhibiting PI3K
activation, wortmannin is only stable for a few minutes
in the cellular environment [20], making the PI3K-
inhibiting effect of LY294002 more apparent in a treat-
ment that lasted 24 h.
One possibility consistent with the observed effect of
PI3K inhibitors on HAstV1 infection is that they may
have led to the inhibition of ERK phosphorylation. PI3K
and MAP kinase pathways are known to crosstalk through
small GTPases such as Ras and Raf1 [21,22]. To evaluate
this possibility, the phosphorylation level of ERK in the
presence or the absence of a PI3K blocker was analyzed
by Western blotting (Figure 2B). We found that, unlike
U0126, which abolished post-infection ERK phosphoryl-
ation (Figure 2B, “pERK” panel in the “U0126” group),
LY294002 did not affect their phosphorylation (Figure 2B,
“pERK” panel of the “LY294002” group). Thus, the PI3K
inhibitor did not exert its effect through an interference
with ERK activation, but acted on a distinct, essential
process in HAstV1 infection.
We then asked whether known downstream targets
of PI3K signaling, such as Akt, play a role in HAstV1
infection. Consistent with PI3K activation in the viral
infection and with Akt being a target of activated PI3K,
the extent of Akt phosphorylation was greater in the
0.25 h and 0.5 h post-infection samples than in the
corresponding mock-infected control (Figure 2A, “pAkt”
and Figure 2C, “Akt”). However, treatment with 10 μM
triciribine (Figure 1B, C and c) or with 10 μM MK2206
(Figure 1B, D and d), both of which are known to inhibit
Akt activation as well as Akt-mediated phosphorylation,
had marginal effects on viral capsid expression. Examin-
ation of the phosphorylation level of Akt in the HAstV1-
infected cells incubated with LY294002, wortmannin,
triciribine, or MK2206 for 24 h showed that all but
triciribine treatment effectively blocked the phosphoryl-
ation of Akt (Additional file 1 and see Discussion). In
addition to the Akt-mediated cascade, Rac1 is also known
Figure 2 (See legend on next page.)
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Figure 2 Importance of timing of kinase inhibition during HAstV1 infection. (A) Time course of activation of MAPKs and Akt. Lysate was
prepared from either mock-infected (Mock) or HAstV1-infected (Infected) Caco-2 cells at designated time points. The lysates were subjected to
Western blot to detect either total kinases (ERK, p38, JNK, and Akt) or their phosphorylated forms [(pERK, pp38, pJNK, and pAkt) MAPKs and Akt].
The two bands in the “ERK” and “pERK” panels represent ERK1 (44 kDa) and ERK2 (42 kDa), respectively. The two bands in “JNK” and “pJNK” panels
represent JNK1 (54 kDa) and JNK2 (46 kDa), respectively. (B) Effect of inhibitors on kinase activation. Lysates prepared at designated time points
from HAstV1-infected Caco-2 cells in the presence of solvent alone (DMSO), LY294002, or U0126 were subjected to Western blot for either total
ERK (ERK) or its phosphorylated form (pERK). ERK1 and 2 bands are indicated by an arrowhead and an arrow, respectively. (C) Quantitative
presentation of the Western blot signal shown in A. Digital images of the bands were quantitated using ImageJ. The vertical line indicates the
relative value of the signal intensity divided by the value of the band for each mock-infected sample, at 0.25 hpi, in each experimental group.
The black and gray bars represent values for the mock- and HAstV1-infected sample, respectively. Note that, due to large differences, the scale of
the vertical bar representing “Akt” differs from that of others. (D) Effects of inhibitors on capsid protein expression. Caco-2 cells were infected and
examined by immunofluorescence analysis as in Figure 1, except that solvent alone or inhibitors were added at indicated time points and
maintained until fixing at 24 hpi. For each time point, the proportions of cells positive for capsid protein expression were examined statistically as
described in Methods. (*P < 0.05; **P < 0.001).
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50 μM NSC23766, an inhibitor of Rac1-specific GEF,
did not interfere with the infection (Figure 1B, E and e).
We also tested for the involvement of other signaling
cascades. H89 blocks the activity of protein kinase A
(PKA) by competing for the ATP binding site of PKA’s
catalytic subunit. Y27632 inhibits Rho-associating pro-
tein kinase (ROCK). Neither inhibitor (at 10 μM and
50 μM, respectively) had an inhibitory effect on viral cap-
sid protein expression (Figure 1B, G and g, and F and f),
indicating that neither the PKA- nor the Rho-mediated
pathway is significant for HAstV1 gene expression.
Inhibitors that block Akt or Rac1 activation did not
prevent the progression of infectious process
The increase in Akt activation at 0.25 and 0.5 h post-
infection suggests that PI3K activation occurs at an early
stage of infection. We also note that there is an increase
of Akt phosphorylation at 8 hpi. To further examine if
PI3K activation is needed in the initial phase of infec-
tion, inhibitors of PI3K, Akt, or Rac1 were added at 0, 2,
or 8 hpi, and the proportion of cells positive for viral
capsid expression was examined by immunofluores-
cence (Figure 2D). The Rac1 inhibitor NSC23766 did
not block viral gene expression at any time point. The
PI3K inhibitors LY294002 and wortmannin were effective
in diminishing viral gene expression only when added at
0 or 2 hpi, at the time range of effectiveness similar to
that of the ERK inhibitor [19]. Neither PI3K inhibitor
was effective at 8 hpi. Although triciribine-treated cells
appeared to exhibit a lower proportion of infected cells,
the difference from the control sample was not signifi-
cant. MK-2206, the other Akt inhibitor, did not affect
viral gene expression (Figure 1B), suggesting that block-
ade of Akt had little effect on HAstV1 infection. None-
theless, the results showing blockade of infection by
PI3K inhibitors added at 0 and 2 hpi are consistent with
the increased phosphorylation of Akt at 15 and 30 min
post-infection seen in the Western blot (Figure 2A),which marks the increased PI3K kinase activity at those
early time points, and suggest that PI3K activation is
important at the initial stage of infection.
Effects of kinase inhibitors on viral RNA replication
The immunofluorescence detection of viral capsid protein
offered a qualitative indication of whether a given kinase
inhibitor affected the initiation of the infection processes
leading to viral gene expression. In order to more quantita-
tively measure the effect of the drugs on viral propagation,
the amount of viral RNA produced in the cells at 24 hpi
in the presence or absence of the drugs was mea-
sured by quantitative real-time RT-PCR (Figure 3A).
Cells treated with genistein, staurosporine, U0126, and
LY294002 contained significantly lower amounts of viral
RNA than cells treated with the solvent alone, consist-
ent with the finding that these drugs were inhibitory to
the expression of viral capsid. Although treatment with
wortmannin could show inhibitory effect on viral capsid
expression (Figure 1B), it did not translate into a signifi-
cant effect on viral RNA replication (see Discussion).
Not surprisingly, drugs that did not inhibit viral gene
expression—inhibitors of MAPK p38s (SB203580), JNK
(JNK inhibitor II), Akt (MK2206), and PKA (H89)—had
no measurable effect on the extent of viral RNA replica-
tion. Treatment with triciribine, NSC23766, or Y27632
induced higher levels of RNA replication and did not
inhibit the production of viral RNA. These results
support the idea that PI3K activation is important for
the initiation of viral infection via a non-Akt, non-Rac
mediated pathway.
Effects of kinase inhibitors on the release of viral RNA
and capsid protein into cell culture supernatant
We next examined the effects of kinase inhibitors on the
release of viral RNA, indicative of virion release, from
the cell by measuring the level of viral RNA present in
the culture supernatant of HAstV1-infected cells at 24 hpi
Figure 3 (See legend on next page.)
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Figure 3 Effects of kinase blockers on viral RNA replication and on the appearance of viral RNA and capsid protein in culture
supernatant. Caco-2 cells were infected with HAstV1 in the absence (Mock) or presence of various kinase inhibitors and examined for the
following. (A) Effects on viral RNA replication. Viral RNA replication in the infected cells was analyzed using quantitative real-time RT-PCR. For each
drug treatment, the quantified amount of viral RNA, normalized to the amount of total RNA, was converted to a value relative to that of mock
treatment. The mean relative value from four independent experiments, with the standard deviation indicated as error bar, is presented. (B)
Effects on presence of viral RNA in culture supernatant. The level of viral RNA in the post-infection culture supernatant was analyzed using real-time RT-
PCR. For each drug treatment, the quantified amount of viral RNA was converted to a value relative to that of mock treatment. The mean relative
value from three experiments, with the standard deviation indicated as error bar, is presented. (C) Effects on presence of viral capsid protein in culture
supernatant. The level of viral capsid antigen in the post-infection culture supernatant was measured using ELISA. The supernatant samples were
prepared in triplicate, and the mean capsid antigen level for each drug treatment was further converted to a value relative to mock treatment.
Statistically significant differences, determined as in Figure 2D, are indicated on the graphs.
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replication analysis, treatment with staurosporine, genis-
tein, U0126, or LY294002 greatly reduced the amount
of viral RNA detected in the supernatant. Wortmannin
treatment also lowered viral RNA content in the super-
natant. Again, the Akt inhibitors triciribine and MK2206
exhibited a contrasting effect; triciribine apparently in-
creased the amount of viral RNA in the culture super-
natant as well as the extent of viral RNA replication
(Figure 3A and B), whereas MK2206 had a marginal
effect on viral RNA accumulation in both the cell and
the culture supernatant. NSC23766 and Y27632, the
inhibitors of Rac1 and ROCK, respectively, similarly
failed to reduce either viral RNA replication or viral
RNA release into the culture supernatant, consistent
with their inability to prevent viral gene expression.
However, the PKA inhibitor H89 showed some inhibi-
tory effect on extracellular viral RNA accumulation,
suggesting that PKA may play a role during virus release
from the cell.
We tested the effects of kinase inhibitors on another
marker for virus production and release, the presence
of viral capsid in the culture supernatant of infected
cells at 24 hpi (Figure 3C). The results are largely con-
sistent with those of the analysis for viral RNA presence
in the culture supernatant (Figure 3B). The same drugs
that inhibited the viral capsid expression—genistein,
staurosporine, U0126, and LY294002—also inhibited
viral capsid accumulation in the culture supernatant.
Wortmannin similarly lowered the level of extracellular
capsid protein, consistent with its lowering of extracellular
viral RNA (Figure 3B, Wortmannin). The contrasting
effect of the Akt inhibitors triciribine and MK2206 seen
in the assays for intracellular viral RNA production and
extracellular viral RNA presence was also detected for
the production of extracellular viral capsid. Again, the
Rac1 and ROCK inhibitors NSC23766 and Y27632 had
no effect, and the PKA inhibitor H89 showed some
inhibitory effect on extracellular viral capsid production,
in agreement with their respective effects on viral RNA
(Figure 3B, NSC23766, Y27632, and H89).Discussion
In this study, a panel of kinase inhibitors was used to iden-
tify the cellular signal transduction pathways important for
HAstV1 infection. We found that inhibitors of PI3K acti-
vation interfered with infection, independent of ERK acti-
vation. We showed that PI3K activation occurred at an
early phase of infection and that the downstream targets
Akt and Rac1 were not required for the infection. Blocking
PI3K with either LY294002 or wortmannin diminished the
production of viral particles, indicating that PI3K activa-
tion is important for HAstV1 infection. In addition, PKA
was involved in some aspect of viral particle production.
Taken together, our results reveal a previously unknown
role of PI3K in establishing HAstV1 infection and PKA on
viral production.
Our data indicate that very early in HAstV1 infection—
within 30 min of the virions’ contact with the cells—
the host Caco-2 cells activate signaling cascades that
involve PI3K. Treating the cells with PI3K-specific in-
hibitors resulted in a block in HAstV1 infection that
was detected at the levels of viral gene expression, viral
RNA replication, and release of viral capsid and RNA
from the cells. Although the phosphorylation of Akt did
not appear to be essential for viral infection, the early time
frame of PI3K activation indicated that PI3K was activated
during an early phase of infection, perhaps at the step
of viral entry. Similarly, ERK activation has been shown
to be important early in HAstV1 infection [19]. Thus,
both PI3K and ERK signaling appears to function dur-
ing an early phase of HAstV1 infection, from viral cell
entry to the initiation of viral gene expression.
During the course of this study, we also found that a
PKA inhibitor decreased the release of viral components
into the culture supernatant, but did not block capsid
protein expression or viral RNA replication. A recent
analysis of human cytomegalovirus infection using kinome
profiling showed that PKA cascades are involved in the
production of progeny virions by regulating the metabolic
pathways of the host cells [23]. It would be interesting
to examine whether PKA cascades metabolically control
HAstV1 production.
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and p38 were phosphorylated shortly after the HAstV1
virion makes contact with the cell, but only the activation
of ERK appears to be essential for infection. Inhibiting ERK
activation with U0126 blocked infection, but inhibiting p38
with SB 203580 did not. Similarly, Akt, one of the major
downstream targets of PI3K, was found to be phosphory-
lated at Ser473 early in HAstV1 infection, though inhi-
bitors of Akt, triciribine, and MK2206 did not seem to
block viral capsid expression, viral RNA replication, or
viral component release. Hence, the activation of p38 and
Akt pathways upon infection appears to be either non-
essential for HAstV1 infection or redundant with other
pathways that could relay the essential signals for the
infectious processes.
It is interesting to note that wortmannin treatment
showed no blockade of RNA replication, but exhibited a
block in viral release. Immunofluorescent detection of viral
capsid protein revealed that treatment with wortmannin
caused unusual punctate staining of the capsid protein,
which suggests that the reagent failed to block viral entry,
but was effective in delaying the process leading to capsid
expression showing aberrant distribution. The time point
examined for viral RNA replication, 24 hpi, may have been
the point when viral RNA replication had already reached
a plateau, but the inhibitory effect of wortmannin on the
release of RNA and virion may have been visible because
of the delay of the infectious process.
Treatment with triciribine enhanced viral RNA replica-
tion in HastV1-infected cells, which possibly caused the
increased viral release that was inferred from the level of
viral RNA and capsid protein in the culture supernatant
(Figure 3). Surprisingly, we found that the Akt phosphor-
ylation was not effectively blocked at 24 hpi (Additional
file 1) and viral capsid release was enhanced in a dose-
dependent manner (Additional file 2). We also noted
that triciribine treatment slightly enhanced cell viability
(Figure 1C). Overall, the treatment appeared to have a
positive effect on viral propagation in our experiments,
rather than an inhibitory effect. Similarly, treatment with
NSC23766 or Y27632 increased the extent of viral RNA
replication. Interestingly, a marked increase in the phos-
phorylated Akt level was observed in cells treated with
each drug (Additional file 1). Akt activation is known to
involve a feedback loop activating Rac1, led by ROCK
inhibition using Y27632 [24]. Because Rho-family sig-
naling events are known to involve balanced regulation
[24], inhibition of another member of the Rho-family,
Rac1, by NSC23766 could also have activated such a
feedback loop. The activated Akt possibly caused an in-
crease in protein synthesis, which could enhance viral
RNA replication [14].
We noted that two Akt phosphorylation inhibitors
affect HAstV1 infection differently. Triciribine apparentlyincreased the amount of viral RNA and the release of viral
RNA and capsid in the culture supernatant, whereas
MK2206 did not (Figure 3). This difference could be
due to a difference in the drugs’ inhibitory mechanisms.
Triciribine inhibits Akt phosphorylation by binding to
the PH domain of Akt, thereby blocking its recruitment
to the plasma membrane [25], whereas MK2206 binds
to the catalytic domain of Akt and inhibits its phosphor-
ylation [26]. Triciribine is also known to inhibit cellular
DNA synthesis [27]. Nonetheless, neither Akt inhibitor
blocked viral infection.
In summary, our study has revealed that two signaling
pathways, mediated by ERK and PI3K, are important for
HAstV1 infection. The observation that specific, selective
PI3K kinase inhibitors did not block ERK phosphoryl-
ation, yet exhibited inhibitory effect on infection, indi-
cates that the PI3K-mediated cascade acts independent
or downstream of that mediated by ERK (Figure 2B).
The involvement of ERK activation is not uncommon in
signaling during viral infection. ERK signaling has been
shown to be important in the mobilization of receptors
for the hepatitis C virus (HCV) [28]; in viral gene expres-
sion for respiratory syncytial virus [29], human cytomegalo-
virus [30], and Kaposi’s sarcoma-associated herpes virus
(KSHV) [31]; in viral genome replication for the influenza
virus [32] and mouse hepatitis virus [33]; in viral assembly
for HCV [34]; and in viral release from host cells for
Borna disease virus [35]. Similarly, PI3K-Akt activation is
needed for viral entry for the influenza virus [36], avian
leucosis retrovirus [37], and vaccinia virus [38], all of
which are also functionally dependent on Akt activation,
unlike the case with HAstV1 infection. An integration
of multiple signaling cascades has been shown for KSHV
infection, in which the FAK-Src-PI3K-PKC-MEK-ERK cas-
cade is involved in viral early gene expression [39], and the
PI3K-Akt-RhoA cascade, but not ERK activation, is im-
portant for viral entry [40]. An integration of the PI3K
and ERK pathways was not observed in HAstV1 infec-
tion; rather, the signaling pathways appeared to be sep-
arate. Because such a pattern of kinase activation during
infection has not been found for other viruses, our study
has uncovered a unique signal transduction strategy of
HAstV1 for establishing infection in host cells.Conclusions
A panel of kinase inhibitors was used to identify the cellu-
lar signal transduction pathways important for HAstV1
infection. Inhibitors that block PI3K activation were found
to interfere with infection, independent of the process of
ERK activation. PI3K activation occurred at an early phase
of infection, and the downstream targets required for the in-
fection were not Akt or Rac1. Moreover, PKA was found to
be involved in some aspects of viral particle production.
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Methods
Virus and cells
The HAstV1 isolate was provided by Dr. Mitsuaki Oseto
(Ehime Hygiene Environmental Institute, Japan). Caco-2
cells (from Dr. Naomi Sakon, Osaka Prefectural Institute
of Public Health, originally given by Dr. Albert Z. Kapikian)
were maintained in a culture medium (EMEM+) consisting
of minimum essential medium with Eagle’s modification
(EMEM) (catalog no. M4655; Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 1 mM sodium pyruvate,
non-essential amino acids (Invitrogen, Green Island, NY,
USA), and 10% fetal bovine serum.
Preparation of virus stocks, quantitation of viral particles,
and measurement of infectious titer
To prepare HAstV1 stocks, Caco-2 cells were infected
with HAstV1 at approximately 100 viral particles per
cell. The culture supernatant was collected 2 days after
infection, freeze-thawed, cleared of cell debris by centri-
fugation, and stored in aliquots as HAstV1 stocks. These
stocks typically contained about 109 particles per mL.
The number of viral particles present in the viral prep-
arations was determined from a measurement of RNA
copy number obtained using real-time quantitative RT-
PCR. Viral RNA was extracted from each sample of the
viral preparations using the QIAamp Viral RNA Mini
Kit (Qiagen, Hilden, Germany). The extracted RNA, along
with a known amount of standard HAstV1 RNA (see
below), was reverse-transcribed into cDNA using the
Superscript III system (Invitrogen) with oligo-dT as the
primer. For quantitating the copy number of the viral
genome, cDNA was amplified using viral cDNA-specific
primers, S3988-4008 (5′-GAGACATCTTTGGCATGT
TGG-3′) and AS4193-4171 (5′-AGGAGCTTCCCATGG
AGTGATTC-3′) with the Thunderbird q-PCR Kit (Toyobo
Life Science, Osaka, Japan). Amplification proceeded
through 40 cycles of denaturation at 94°C for 15 s,
annealing at 62°C for 20 s, and extension at 72°C for
20 s in either a LightCycler 2.0 (Roche Applied Science,
Penzberg, Germany) or a CFX-96 (Bio-Rad, Hercules,
CA, USA). The cDNA copy number, derived from the
fluorescence signals of the amplification products, was
then converted into particle number.
Standard HAstV1 RNA was prepared by in vitro tran-
scription using a T7 RiboMax Express Large Scale RNA
Production System (Promega) and the template DNA
pAVIC V (a gift of Dr. Albert Bosch, University of
Barcelona), which harbors a molecular clone of HAstV1.
Infectious titer was determined using the method de-
scribed by Mendez et al. [8]. In our study, infection with
100 particles per Caco-2 cell yielded approximately 20%of the cells positive for anti-HAstV1 antibody at 24 hpi.
From this value, the multiplicity of infection (MOI) was
calculated to be approximately 0.22.
Infection and drug treatment
Prior to infection, confluent Caco-2 cells maintained in
EMEM+were washed with PBS (−) thrice and starved
of serum for 1 h by incubation in EMEM supplemented
with sodium pyruvate, non-essential amino acids, and
20 mM HEPES (EMEM−). HAstV1 stock was pretreated
with 10 μg/mL trypsin IV (catalog no. T4799; Sigma-
Aldrich) for 15 min at 37°C, and then applied to the cells
along with trypsin at approximately 100 particles per cell.
The mixture was then incubated for 1 h at 4°C, which
was intended to allow the virus to bind the cells, but not
proceed further in the entry process. We noted that this
procedure has been described in Moser and Schulz-
Cherry [19] and that incubation at 4°C for 1 h did not
substantially alter the infectious events seen when incu-
bating at 37°C, judged by the number of cells positive
for viral antigen after staining with mouse anti-HAstV1
antibody (Data not shown). After removal of the cul-
ture medium and washing with EMEM–, incubation of
the cells was continued in EMEM– supplemented with
10 μg/mL trypsin IV until the time of harvest. For
experiments involving pharmacological inhibitors, the
infection of Caco-2 cells was carried out in the presence
of a specified drug for a designated time period (i.e., with
the inhibitor present during both the incubation with
virus and the subsequent EMEM–/trypsin IV incubation).
Genistein, U0126, JNK inhibitor II, H-89, Akt inhibi-
tor V (triciribine), and Y-27632 were purchased from
Merck (Whitehouse Station, NJ, USA). Wortmannin and
staurosporine were from Sigma-Aldrich. SB203580 and
LY294002 were obtained from Promega (Fitchburg, WI,
USA). NSC23766 and MK-2206 were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) and Selleckchem
(Houston, TX, USA), respectively. All drugs were sol-
ubilized in dimethyl sulfoxide (DMSO). Initial drug con-
centrations were selected after consulting the following
references: staurosporine [41], genistein [42], U0126 [19,43],
SB205830 [19], JNK inhibitor II [44], LY294003 [43],
wortmannin [45], triciribine [46], MK-2206 [47], NSC23766
[48], Y-27632 [43], and H-89 [49]. The appropriate con-
centrations of some drugs were determined empirically
by examining their inhibitory effect on HAstV1 infec-
tion using immunofluoresent detection of viral capsid-
positive cells (Additional file 3) or ELISA for the extent
of viral capsid proteins released from HAstV1-infected
Caco-2 cells infected with HAstV1 (Additional file 2).
Immunofluorescence detection of viral capsid protein
Infected cells were fixed with either acetone-methanol
or 4% paraformaldehyde in PBS without magnesium or
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(catalog no. sc-53559; Santa Cruz Biotechnology) in PBS
containing 0.5% TritonX-100. Goat anti-mouse IgG conju-
gated with AlexaFluor 488 (catalog no. A-11017; Invitrogen,)
was used as the secondary antibody. Immunostained
cells were examined under the epifluorescent microscope
BZ1000 (Keyence, Osaka, Japan) and immunofluorescence
images were prepared using Adobe Photoshop (Adobe
Systems, Mountain View, CA, USA). For quantitation
of viral infection, approximately two hundred cells were
counted in at least three different areas, and the proportion
of HAstV1 capsid-positive cells within the counted cells
was used for statistical analysis (see below).
Measurement of cell viability
Viability of cells infected with HAstV1 in the absence
or presence of inhibitors was examined using a cell pro-
liferation assay kit (WST-1 cell proliferation assay kit;
Takara, Otsu, Japan), which is based on the cleavage of a
tetrazolium salt by mitochondrial dehydrogenases to form
formazan in viable cells. Designated dose of WST-1 [2-(4-
Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium] was added to the cell culture at 20 hpi and
incubation was continued for an additional 4 h. The cell
culture medium was then measured for absorbance at
450 nm versus a 650 nm reference using a SpectraMax
M5 microplate reader (Molecular Devices, Sunnyvale,
CA, USA).
Western blot analysis of phosphorylated MAPKs and Akt
The protein content of infected cell lysates was quantified
by either the Bradford method (Takara) using a BCA Pro-
tein Quantitation Kit (Thermo Fisher Scientific, Waltham,
MA, USA) or the Qubit fluorometric quantitation system
for protein (Invitrogen). Then, cell lysate samples con-
taining the same amount of protein were separated using
12.5% SDS-polyacrylamide gels, transferred onto PVDF
membranes, and probed for MAPKs or Akt using specific
antibodies. The primary antibodies, all obtained from Cell
Signaling (Beverly, MA, USA) include the following: three
rabbit antibodies from the MAPK family antibody sam-
pler kit (catalog no. 9926S), anti-p44/42 MAPK (ERK1/2;
clone 137 F5), anti-SAPK/JNK (clone 56G8), or anti-p38
MAPK; three rabbit antibodies from the Phospho MAPK
family antibody sampler kit (catalog no. 9910S), anti-
phospho-p38 MAPK (Thr180/Tyr182; clone D2F9), anti-
phospho-p44/42 MAPK (ERK1/2; Thr202/Tyr294; clone
D13.14.4E), or anti-phospho-SAPK/JNK (Thr183/Tyr185;
clone 81E11); rabbit anti-Akt antibody (catalog no. 4691;
clone C67E7); and anti-phospho-Akt (Ser473) antibody
(catalog no. 4060; clone D9E). A secondary antibody
against rabbit IgG, conjugated with horseradish peroxidase
(HRP; Cell Signaling) was used in all cases, and signal
was detected using enzyme-linked chemiluminescencewith Immunostar (Wako Pure Chemical Industries, Osaka,
Japan) and exposing the blot to X-ray film to visualize
bands. The membranes were first probed for phosphor-
ylated kinases, and then reprobed for total amount of
kinases. Restore Plus Western Blot Stripping Buffer
(Thermo Fisher Scientific, Waltham, MA, USA) was used
to strip the antibodies from the blot. The chemilumines-
cent signal was quantified from densitometric readings
of digital images (using ImageJ software) retrieved by
scanning the X-ray film.
Quantitation of viral RNA present in cells and cell culture
supernatants
RNA was purified from infected cells using the Nucleospin
RNA Kit (Macherey-Nagel, Düren, Germany). The ex-
tracted RNA was quantified using a spectrophotometer
(Nanodrop2000; Thermo Fisher Scientific), and a fixed
amount of total RNA was used for quantitation of viral
RNA. For culture supernatants, RNA was purified from
the conditioned medium collected 24 h after infection
using the QIAamp Viral RNA Mini Kit (Qiagen). The viral
RNA was quantified using the OneStep SYBR PrimeScript
Plus RT-PCR Kit with the primer set S3988-4008 and AS
4193–4171 (see above), along with a known amount of
in vitro transcribed HAstV1 RNA as a standard. The level
of amplification of the ORF1 region was then converted to
the quantity of full-length viral RNA.
Enzyme-linked immunobsorbant assay (ELISA) for viral
capsid
The culture supernatants of infected cells were exam-
ined for the presence of viral capsid by ELISA. In brief,
50 μL of conditioned medium from infected cultures
was applied to each well, incubated overnight at 4°C in
microtiter plates (Nunc-Immuno Plate MaxiSorp; Thermo
Fisher Scientific), washed with PBS (−) containing 0.1%
Tween 20, and incubated with mouse anti-HAstV IgG
(3 μg/ml) in a blocking solution (StartingBlock Blocking
Buffer in TBS with Tween 20; catalog no. 37543; Thermo
Fisher Scientific) for 1 h at 37°C. After being washed, the
wells were incubated with a 5000-fold dilution of HRP-
conjugated sheep anti-mouse antibody (GE Healthcare,
Waukesha, WI, USA) in the blocking solution for 1 h at
37°C, followed by incubation with an HRP-colorimetric
substrate (TMB Microwell Peroxidase Substrate System;
catalog no. 50-76-00; KPL, Gaithersburg, MD, USA) at
room temperature. The colorimetric reaction was stopped
using TMB Stop Solution (catalog no. 50-85-05; KPL)
and the absorbance was measured using a SpectraMax
M5 microplate reader (Molecular Devices).
Statistical analysis
ANOVA was used to examine statistical variance between
experimental groups. The variance between individual
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of < 0.01 or <0.05 were considered significant and indi-
cated in graphs.
Additional files
Additional file 1: Blockade of Akt phosphorylation at 24 hpi in
HAstV1-infected Caco-2 cells by inhibitors of PI3K and Akt. Caco-2
cells infected with HAstV1 were incubated for 24 h in the presence or
absence of the indicated inhibitors. The cells were then harvested, and equal
amount of the protein was separated through 12.5% SDS-polyacrylamide
gels, followed by transfer to a PVDF membrane for Western blot. The
membrane was probed for phosphorylated Akt (pAKT) and then reprobed
for total Akt (Akt), as described in the Methods section.
Additional file 2: Effects of varying drugs doses on the extent of
HAstV1 capsid release at 24 hpi. The dose–response effects on HAstV1
infection from treatment with genistein, U0126, LY294002, wortmannin,
triciribine, MK2206, H89, and Y27632 were examined by measuring viral
capsid release in culture supernatants at 24 hpi using ELISA. Drug
concentrations (μM) are indicated at the bottom of each bar. Each bar
indicates a value relative to that obtained with treatment of solvent
alone (DMSO). The mean of three different samples is shown with the
standard deviation. Values indicating a statistically significant difference
from “mock” are marked (*P < 0.05; **P < 0.01).
Additional file 3: Effects of varying drug doses on viral capsid
expression 24 h after HAstV1 infection. Kinase inhibitors, at different
concentrations, were added to Caco-2 cells upon HAstV1 infection, and
the effects on the viral capsid expression were examined as in Figure 1.
The proportion of cells positive for viral capsid in a sample of approximately
200 cells was divided by the proportion obtained from cells infected with
HAstV1 alone (“Mock”). The mean values obtained by counting at three
different spots on the coverslip is shown as a bar; error bars represent the
standard deviation. The drug and the concentration used is shown at the
bottom of each bar. Values that show a statistically significant difference
from that of the “mock” are marked as ** (P < 0.01).
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